Thermo Fisher Scientific Inc. research snapshot
TMO AI stock analysis as of the August 2, 2026 data cutoff reads Thermo Fisher Scientific as a high-quality life sciences tools, diagnostics, analytical instruments, and biopharma services platform that delivered an outstanding second quarter. The stock closed at $574.30 on July 31, 2026 at a market capitalization near $212.35 billion, re-verified as $574.30 times 369.75 million shares with a 0.00% deviation. The Q2 2026 report, released July 23, 2026, beat estimates with revenue of $11.99 billion up 10%, organic revenue growth of 5%, adjusted operating income of $2.73 billion up 15%, and adjusted EPS of $6.03 up 13%, with GAAP EPS of $4.68 up 9%. Management raised full-year 2026 guidance to revenue of $47.4 billion to $48.1 billion and adjusted EPS of $24.93 to $25.33, reflecting about 4% organic growth and 9% to 11% adjusted EPS growth. Offsetting this is a premium valuation near 30.9x trailing earnings and 21.9x forward earnings, roughly $38.5 billion of net debt on the June 27, 2026 balance sheet with leverage near 3.3x net debt to adjusted EBITDA, a pending microbiology divestiture, and the risk that the life sciences recovery slows. The page presents a scenario framework, not a certain price prediction, and is for information only.
Current price
$574.30
Market cap
$212.35 billion verified market cap
AI score
74 / 100
Rating
Improving life sciences momentum at a premium valuation
Trend status
Bullish trend above the 20-day, 50-day, 100-day, and 200-day moving averages
Data cutoff (updated monthly)
August 4, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Thermo Fisher sells tools, consumables, instruments, diagnostics, lab services, CDMO services, and CRO services that sit inside recurring scientific, pharma, biotech, academic, government, and clinical workflows. Q2 2026 delivered broad-based growth across all four segments. | High |
| Moat | The moat comes from scale, breadth, trusted brands, workflow integration, regulated customer qualification, recurring consumables, procurement convenience, and the PPI operating system. | High |
| Management | Marc Casper has been chairman and CEO for more than 15 years, and the team closed Clario, integrated filtration and separation, agreed to divest microbiology, and returned $1.2 billion to shareholders in Q2 while raising guidance. | High |
| Financial trend | Q2 2026 revenue grew 10% to $11.99 billion with 5% organic growth, adjusted EPS grew 13% to $6.03, adjusted operating margin expanded 90 basis points to 22.8%, and FY2026 guidance was raised to $47.4 to $48.1 billion revenue and $24.93 to $25.33 adjusted EPS. | High |
| Valuation | At $574.30, TMO screens near 30.9x trailing EPS, 21.9x forward earnings, 4.03x book value, 4.58x sales, and 29.02x trailing free cash flow, which is a premium for the sector. | Medium |
| Technical trend | TMO closed at $574.30 on July 31, 2026, above its 20-day, 50-day, 100-day, and 200-day moving averages, with 14-day RSI near 68.71 and 14-day ADX near 30.98 confirming a confirmed uptrend. | Medium |
| Risk level | Risks include a premium valuation, roughly $38.5 billion of net debt, Clario and filtration and separation integration, the microbiology divestiture, biotech funding cycles, China at about 7.5% of revenue, and possible multiple compression. | Medium-high |
| AI confidence | High for descriptive facts and cross-checked math that matched across StockAnalysis.com, SEC EDGAR XBRL, the Q2 2026 earnings release, and the earnings call transcript. Lower for forward return estimates because multiples and end-market assumptions are uncertain. | High data confidence |
| Investment certainty | Medium certainty. TMO is a quality compounder with improving momentum, but the premium valuation and elevated leverage mean the current price already prices in a lot of good news. | Medium |
TMO AI stock forecast
The TMO AI stock forecast uses scenario math around the July 31, 2026 close of $574.30 and the raised FY2026 adjusted EPS guidance midpoint of $25.13. The three-scenario framework produced a bearish area near $467, a base area near $696, and a bullish area near $937 before dividends, using adjusted EPS growth of 3%, 8%, and 10% and exit multiples of 17x, 22x, and 28x over three years. These are scenarios, not price commitments.
$870 to $990
More likely if organic revenue growth stays near or above 5%, biotech funding and academic budgets keep improving, Clario and filtration and separation scale on schedule, China returns to growth, and investors hold TMO near a mid-20s to high-20s earnings multiple.
$660 to $730
More likely if Thermo Fisher grows organic revenue around 4%, compounds adjusted EPS at a high single-digit to low double-digit rate, keeps the $47.4 to $48.1 billion revenue and $24.93 to $25.33 EPS guidance on track, and the stock holds near a low-20s forward multiple.
$400 to $480
More likely if the life sciences recovery stalls, biotech funding and academic budgets weaken again, China disappoints, acquisition integration or the microbiology divestiture drags on earnings, leverage limits buybacks, or the market compresses the multiple toward the high-teens.
TMO AI technical analysis
TMO AI technical analysis is bullish as of the August 2, 2026 data cutoff. The stock closed at $574.30 on July 31, 2026, above its 20-day moving average near $542.49, its 50-day near $504.81, its 100-day near $493.31, and its 200-day near $530.72, with 14-day RSI near 68.71 and 14-day ADX near 30.98. The 52-week range is $435.27 to $643.99, so the next major resistance is the high near $643.99.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $574.30 | Market-data reference from the July 31, 2026 close, used for valuation and market-cap checks at the August 2, 2026 data cutoff. |
| Near support | $538 to $546 | This zone brackets the 20-day moving average near $542.49 and is the first level to watch on a pullback. |
| Next support | $525 to $533 | The 200-day moving average near $530.72 sits in this zone and defines the medium-term trend line. |
| Deeper support | $493 to $510 | The 100-day moving average near $493.31 and the 50-day moving average near $504.81 form a deeper support cluster. |
| Near resistance | $640 to $650 | The 52-week high near $643.99 is the immediate upside test and the first major resistance. |
| Higher resistance | $740 to $750 | The analyst high target near $750 marks the next reference above the 52-week high. |
| Moving averages | 20-day $542.49, 50-day $504.81, 100-day $493.31, 200-day $530.72 | Price is above all four major moving averages, which turns the setup from a rebound into a confirmed uptrend. |
| Momentum | RSI near 68.71 | 14-day RSI is strong but not yet overbought, while the 9-day RSI near 70.19 shows momentum is stretched after the post-earnings rally. |
| Volume | 20-day average near 2.19 million shares | Volume near 2.19 million shares on StockAnalysis.com and 2.24 million shares on Barchart supports the move, and a volume-confirmed breakout would strengthen the trend. |
| Volatility | 14-day ATR near $17.54 | Historic volatility near 39% on Barchart means wider swings around earnings and guidance, so position sizing should account for larger daily ranges. |
| Invalidation | Close below $530, then below $493 | A close below the 200-day moving average near $530.72 would weaken the uptrend, and a break below the 100-day near $493.31 would turn the technical setup bearish. |
TMO AI trading strategy
The TMO AI trading strategy below is a rules-based research framework, not personalized advice. It connects price behavior with life sciences demand, organic growth, acquisition integration, free cash flow, leverage, the microbiology divestiture, China exposure, and valuation discipline.
Watch for TMO to hold above the 20-day moving average near $542 and to build volume on a move toward the $643.99 high while Q3 results confirm organic growth, adjusted EPS progress, and stable guidance.
A close below the 20-day moving average, and then below the 200-day near $530, should reduce trend confidence, especially if management commentary points to weaker biotech funding, academic budgets, or China softness.
If TMO pulls back toward the $493 to $510 support cluster without damage to organic demand, cash generation, or the guidance path, compare the lower price with Thermo Fisher quality and the base-case valuation range.
Do not treat a lower price as automatically attractive if EPS revisions fall, debt reduction slows, acquisition integration disappoints, or organic growth stays below the 4% guidance area.
Track Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, Laboratory Products and Biopharma Services, organic growth, biotech and academic funding, China demand, Clario and filtration and separation integration, free cash flow, and leverage.
Position sizing should reflect that TMO is a high-quality but cyclically exposed life sciences infrastructure company with meaningful debt after the Clario deal, not a guaranteed defensive growth trade.
Investment research summary
Customers pay Thermo Fisher because scientific research, pharma development, diagnostics, laboratory operations, and biopharma services require reliable tools, consumables, instruments, software, and outsourced capabilities that reduce workflow risk and speed discovery.
The moat is strongest in scale, brand trust, procurement breadth, installed workflows, regulated qualification, recurring consumables, service networks, and acquisition integration. It is weaker where capital equipment demand turns cyclical.
The thesis fails if the life sciences recovery stalls, biotech funding and academic budgets weaken, China disappoints, Clario or filtration and separation integration consumes capital, the microbiology divestiture drags, debt limits buybacks, or investors stop paying a premium multiple.
Marc Casper has led the company for more than 15 years and has overseen portfolio expansion through Life Technologies, Patheon, PPD, Olink, Clario, and filtration and separation. The key test is whether the next phase balances acquisitions, debt reduction, buybacks, and the pending divestiture while keeping organic growth near or above 4%.
Thermo Fisher benefits from long-term growth in biologics, diagnostics, precision medicine, analytical testing, pharma outsourcing, and lab automation, and Q2 2026 showed customer activity strengthening across pharma and biotech, academic and government, industrial and applied, and diagnostics and healthcare.
At $574.30, the market is paying a premium for sustained execution and a continued recovery in organic growth. Margin of safety improves if the stock pulls back toward the base-case range while free cash flow and leverage improve.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| TMO price reference | $574.30 at the July 31, 2026 close | StockAnalysis.com real-time quote | August 2, 2026 |
| Market capitalization verification | $212.35 billion, verified as $574.30 x 369.75 million shares with 0.00% deviation | financial_rigor.py market cap verification | August 2, 2026 |
| Shares outstanding | 369.75 million shares outstanding, down 1.45% year over year | StockAnalysis.com statistics | August 2, 2026 |
| Q2 2026 revenue | $11.99 billion, up 10% with 5% organic growth and 5% from acquisitions | Thermo Fisher Q2 2026 earnings call | July 23, 2026 |
| Q2 2026 adjusted EPS and GAAP EPS | Adjusted EPS $6.03 up 13%, GAAP EPS $4.68 up 9%, adjusted operating income $2.73 billion up 15% | Thermo Fisher Q2 2026 earnings call | July 23, 2026 |
| Q2 2026 segment performance | Life Sciences Solutions reported up 13% with 3% organic, Analytical Instruments up 7% with 7% organic, Specialty Diagnostics up 6% with 5% organic, Laboratory Products and Biopharma Services up 12% with 5% organic | Thermo Fisher Q2 2026 earnings call | July 23, 2026 |
| FY2026 guidance raised | Revenue $47.4 to $48.1 billion, adjusted EPS $24.93 to $25.33, organic growth about 4%, free cash flow $6.9 to $7.4 billion | Thermo Fisher Q2 2026 earnings call | July 23, 2026 |
| Q2 2026 capital returns | $1.2 billion returned to shareholders, including $1 billion in buybacks and about $175 million in dividends | Thermo Fisher Q2 2026 earnings call | July 23, 2026 |
| Clario and portfolio actions | Clario closed in late March 2026 with a strong Q2, filtration and separation integrating well, microbiology divestiture expected to close in Q3 2026 with 2026 revenue impact of about $200 million net | Thermo Fisher Q2 2026 earnings call | July 23, 2026 |
| Cash and cash equivalents | $4.06 billion as of June 27, 2026 | StockAnalysis.com balance sheet and Q2 2026 Form 10-Q | August 2, 2026 |
| Total debt | $42.55 billion as of June 27, 2026, with $3.37 billion short-term and $39.18 billion long-term | StockAnalysis.com balance sheet and Q2 2026 Form 10-Q | August 2, 2026 |
| Net debt | -$38.49 billion, calculated as cash of $4.06 billion minus total debt of $42.55 billion | financial_rigor.py exact calculator | August 2, 2026 |
| TTM revenue and EPS | $46.34 billion revenue and $18.58 EPS | StockAnalysis.com statistics | August 2, 2026 |
| FY2025 revenue | $44.56 billion, up 3.91% from $42.88 billion, with FY2025 adjusted EPS of $22.87 | StockAnalysis.com overview and financial statements | August 2, 2026 |
| Valuation check | 30.90x trailing PE, 21.87x forward PE, 4.58x sales, 4.03x book value, 29.02x free cash flow, 0.33% dividend yield | financial_rigor.py valuation verification | August 2, 2026 |
| Technical references | 20-day MA $542.49, 50-day MA $504.81, 100-day MA $493.31, 200-day MA $530.72, RSI 68.71, 20-day average volume 2.19 million | StockAnalysis.com statistics and Barchart | August 2, 2026 |
| 52-week range | $435.27 to $643.99 | StockAnalysis.com TMO overview | August 2, 2026 |
| Analyst consensus | Buy with an average target of $627.62 across 28 analysts, low $520 and high $750, median $632.50 | StockAnalysis.com forecast | July 29, 2026 |
| Analyst rating mix, July 2026 | 18 Strong Buy, 3 Buy, 7 Hold, 0 Sell out of 28 analysts | StockAnalysis.com forecast recommendation trends | July 29, 2026 |
| Recent analyst target updates | J.P. Morgan $690, CMB International $620 to $660, Piper Sandler $510 to $600, Morgan Stanley $620 to $650, Stifel $600, Barclays $625 to $650, BofA $630 to $650, Jefferies $585 to $630, RBC $490 to $580 | StockAnalysis.com forecast latest forecasts | July 29, 2026 |
| 2026 and 2027 consensus estimates | FY2026 revenue $47.84B with adjusted EPS $25.11, FY2027 revenue $50.30B with adjusted EPS $27.49 | StockAnalysis.com forecast financial forecast | July 29, 2026 |
| Short interest | 5.30 million shares short, 1.43% of shares outstanding, 2.52 days to cover | StockAnalysis.com statistics short selling | August 2, 2026 |
This TMO AI stock analysis is an informational research tool, not investment advice, a recommendation, or a promise of future returns. Forecast ranges are scenarios based on available public data as of August 2, 2026 and can be wrong if earnings, guidance, interest rates, end-market demand, acquisitions, regulations, or market sentiment change.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
